SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
dom12149-sup-0001-AppendixS1.docWord document31KAppendix S1. Eligibility criteria and the method for sample size calculation are provided in the Supporting Information.
dom12149-sup-0002-FigureS1.tifTIFF image14434KFigure S1. HbA1c (A), FPG (B), urinary glucose/creatinine ratio (C) and body weight (D) measured at the start (except for urinary glucose/creatinine ratio and body weight) and end of the run-in period and during the 12-week treatment period. HbA1c, haemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; FPG, fasting plasma glucose; UGE, urinary glucose excretion; CRE, creatinine.
dom12149-sup-0003-FigureS2.tifTIFF image12108KFigure S2. Plasma glucose levels measured during the meal tolerance tests performed at baseline (end of the run-in period) and at week 12 in the treatment period in the placebo (A), 50 mg (B), 100 mg (C), 200 mg (D) and 300 mg (E) canagliflozin groups. The meal was consumed at 0 min.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.